Primary Peritoneal Carcinoma Recruiting Phase 2 Trials for Cobimetinib (DB05239)

IndicationStatusPhase
DBCOND0028874 (Primary Peritoneal Carcinoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03363867BEACON - Targeting the C1 Subtype of High Grade Serous Ovarian CancerTreatment